NCT00988650

Brief Summary

While there is now undisputable evidence relating elevated plasma low-density lipoprotein (LDL) cholesterol levels to an increased risk of coronary heart disease (CHD), it is being increasingly recognized that a significant proportion of CHD events occur in individuals characterized by a cluster of additional metabolic and physiological perturbations now defined as the metabolic syndrome. Epidemiological and clinical evidence have shown us that nutritional factors, often in conjunction with obesity, play a pivotal role in the pathophysiology of the metabolic syndrome. In that regard, accumulating evidence suggest that a Mediterranean-style diet (MedDiet) may beneficially modify several components of the metabolic syndrome including plasma triglycerides (TG) and high-density lipoprotein (HDL) cholesterol levels, insulin resistance, waist circumference and markers of vascular inflammation. However, the physiological mechanisms underlying the cardioprotective effects of the MedDiet on features of the metabolic syndrome and the importance of body weight reduction in maximizing these effects represent key issues that have yet to be investigated. The general objective of the study is to investigate for the first time in a controlled feeding study the mechanisms and factors underlying the impact of the MedDiet, with and without weight loss on the dyslipidemic features of the metabolic syndrome.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
26

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started May 2007

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

May 1, 2007

Completed
1.6 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2008

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2008

Completed
10 months until next milestone

First Submitted

Initial submission to the registry

September 25, 2009

Completed
7 days until next milestone

First Posted

Study publicly available on registry

October 2, 2009

Completed
Last Updated

March 5, 2013

Status Verified

March 1, 2013

Enrollment Period

1.6 years

First QC Date

September 25, 2009

Last Update Submit

March 4, 2013

Conditions

Keywords

Metabolic syndromeMediterranean dietBlood lipidsCoronary heart diseaseApolipoprotein

Outcome Measures

Primary Outcomes (1)

  • plasma LDL, TG and HDL-C

    Week 5, 10 and 35 (at the end of each weight-maintaining diet)

Secondary Outcomes (1)

  • CRP, and blood pressure, kinetic of lipoproteins

    Week 5, 10 and 35 (at the end of each weight-maintaining diet)

Study Arms (4)

North American diet

ACTIVE COMPARATOR

Control North American diet for five weeks in isocaloric conditions

Other: isocaloric diet

Mediterranean diet

EXPERIMENTAL

Mediterranean diet for five weeks in isocaloric conditions

Other: isocaloric diet

weight loss period

EXPERIMENTAL

Weight loss period of 20-week (minimum 5% reduction in body weight)

Other: free living conditions

Weight stabilizing mediterranean diet

ACTIVE COMPARATOR

Mediterranean diet for five weeks in isocaloric weight stabilizing conditions

Other: isocaloric diet

Interventions

Also known as: 3 isocaloric die
Mediterranean dietNorth American dietWeight stabilizing mediterranean diet
Also known as: weight lost free living conditions
weight loss period

Eligibility Criteria

Age18 Years - 65 Years
Sexmale
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Men from the Québec City metropolitan area with the metabolic syndrome based on the NCEP-ATP III definition (3 criteria or more see below):
  • Waist circumference ≥ 102 cm
  • Triglycerides ≥ 1.7 mmol/L
  • HDL-cholesterol \<= 1.04 mmol/L
  • Systolic blood pressure ≥ 130 mmHg or diastolic blood pressure ≥ 85 mmHg
  • Fasting blood glucose ≥ 5.6 mmol/L
  • Stable body weight (+/- 2 kg) for 6 months before the beginning of the study

You may not qualify if:

  • Previous history of cardiovascular disease, type 2 diabetes and monogenic dyslipidemia
  • Subjects taking medications for hyperlipidemia or hypertension
  • Endocrine disorders
  • Food allergies or aversion for specific components of the MedDiet
  • Smokers
  • Consummation excessive of alcohol (\> 2 consummation/day)

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Institute of Nutraceutical and Functional Foods (INAF), Laval University

Québec, Quebec, G1V 0A6, Canada

Location

Related Publications (4)

  • Richard C, Couture P, Desroches S, Nehme B, Bourassa S, Droit A, Lamarche B. Effect of an isoenergetic traditional Mediterranean diet on the high-density lipoprotein proteome in men with the metabolic syndrome. J Nutrigenet Nutrigenomics. 2014;7(1):48-60. doi: 10.1159/000363137. Epub 2014 Jul 4.

  • Richard C, Couture P, Desroches S, Lichtenstein AH, Lamarche B. Effect of an isoenergetic traditional Mediterranean diet on apolipoprotein A-I kinetic in men with metabolic syndrome. Nutr J. 2013 Jun 7;12(1):76. doi: 10.1186/1475-2891-12-76.

  • Richard C, Couture P, Ooi EM, Tremblay AJ, Desroches S, Charest A, Lichtenstein AH, Lamarche B. Effect of Mediterranean diet with and without weight loss on apolipoprotein B100 metabolism in men with metabolic syndrome. Arterioscler Thromb Vasc Biol. 2014 Feb;34(2):433-8. doi: 10.1161/ATVBAHA.113.302185. Epub 2013 Nov 21.

  • Richard C, Couture P, Desroches S, Lamarche B. Effect of the Mediterranean diet with and without weight loss on markers of inflammation in men with metabolic syndrome. Obesity (Silver Spring). 2013 Jan;21(1):51-7. doi: 10.1002/oby.20239.

MeSH Terms

Conditions

Cardiovascular DiseasesMetabolic SyndromeCoronary Disease

Condition Hierarchy (Ancestors)

Insulin ResistanceHyperinsulinismGlucose Metabolism DisordersMetabolic DiseasesNutritional and Metabolic DiseasesMyocardial IschemiaHeart DiseasesVascular Diseases

Study Officials

  • Benoît Lamarche, PhD

    Institute of Nutraceutical and Functional Foods (INAF), Laval University

    STUDY DIRECTOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NON RANDOMIZED
Masking
NONE
Purpose
PREVENTION
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Professor

Study Record Dates

First Submitted

September 25, 2009

First Posted

October 2, 2009

Study Start

May 1, 2007

Primary Completion

December 1, 2008

Study Completion

December 1, 2008

Last Updated

March 5, 2013

Record last verified: 2013-03

Locations